Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration MedDRA version: 20.0 Level: PT Classification code 10075567 Term: Dry age-related macular degeneration System Organ Class: 10015919 - Eye disorders
Conditions
Interventions
Product Name: Zimura
Product Code: ARC1905
Pharmaceutical Form: Solution for injection
INN or Proposed INN: avacincaptad pegol
Current Sponsor code: Zimura
Other descriptive name: ARC1905
Concentratio
Sponsors
IVERIC bio
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Ophthalmic Inclusion Criteria The following inclusion criteria apply to the SE: - Non-foveal GA secondary to dry AMD. - The atrophic lesion must be able to be photographed in its entirety. - Best corrected visual acuity in the SE between 20/25 – 20/320, inclusive. General Inclusion Criteria - Subjects of either gender aged =50 years. - Women must be using two forms of effective contraception, be post-menopausal for at least 12 months prior to trial entry, or surgically sterile; if of child-bearing potential, a serum pregnancy test must be performed within 14 days prior to the first injection with a negative result. The two forms of effective contraception must be implemented during the trial and for at least 60 days following the last dose of test medication. - Provide written informed consent. - Ability to return for all trial visits. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 70 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 207
Exclusion criteria
Exclusion criteria: Exclusion Criteria Subjects will not be eligible for the trial if subjects cannot attend all trial required visits, or if any of the following criteria are present systemically or in the SE: Ophthalmic Exclusion Criteria The following exclusion criteria apply to the SE: - Evidence of CNV in either eye. - Any prior treatment for AMD or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals. - Presence of other causes of choroidal neovascularization. - Any intraocular surgery or thermal laser within 3 months of trial entry. Any prior thermal laser in the macular region, regardless of indication. - Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks. - Any sign of diabetic retinopathy in either eye.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The objectives of this study are to evaluate the safety and efficacy of Zimura™ intravitreous administration when administered in subjects with geographic atrophy secondary to dry age-related macular degeneration (AMD).;Secondary Objective: Not Applicable;Primary end point(s): Primary Efficacy Endpoint: Mean rate of change in GA over 12 months measured by FAF at three time points: Baseline, Month 6, and Month 12 Safety Endpoints: - AEs - Vital signs (pulse, systolic and diastolic blood pressure) - Ophthalmic variables (IOP, ophthalmic examination, FA, FAF, and OCT) - ECG (12-lead) - Laboratory variables (blood: hematology, renal function, hepatic function, and electrolytes; urinalysis);Timepoint(s) of evaluation of this end point: Primary Efficacy Endpoint: From Baseline to Month 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Secondary Efficacy Endpoints: - The mean change in best corrected visual acuity (ETDRS letters) from Baseline to Month 12 - Mean change in low luminance best corrected visual acuity (ETDRS letters) from Baseline to Month 12;Timepoint(s) of evaluation of this end point: From Baseline to Month 12 | — |
Countries
Croatia, Czech Republic, Estonia, Hungary, Israel, Latvia, United States
Contacts
Public ContactVP Global Regulatory Affairs
IVERIC bio
Outcome results
None listed